NeuroNEXT Small Business Innovation in Clinical Trials (U44 Clinical Trial Optional) | PAR 25 133

FAQs: NeuroNEXT Small Business Innovation in Clinical Trials (PAR-25-133)

What is PAR-25-133?

PAR-25-133 is an NIH funding announcement titled the NeuroNEXT Small Business Innovation in Clinical Trials opportunity. It supports small businesses that want to run exploratory clinical trials of investigational interventions for neurological conditions, with the goal of producing early human clinical data.

What is the main purpose of this opportunity?

The purpose is to help small companies generate early clinical evidence in humans that can justify moving to larger and more definitive studies. It is intended to produce results that help properly design later-stage trials and reduce development risk at an early clinical stage.

What type of award mechanism is used?

This opportunity uses a cooperative agreement mechanism (U44). Under a cooperative agreement, NIH staff typically have substantial involvement during the project compared with a standard grant mechanism.

What does "substantial NIH involvement" generally mean in this context?

Because the award is a cooperative agreement (U44), NIH staff are expected to play a more active role during the project than they would under a traditional grant. The specific areas of involvement would be governed by the terms and expectations described in the full funding announcement.

What kinds of studies are supported?

The program supports exploratory clinical trials that evaluate investigational interventions for neurological conditions. These trials are meant to answer early, practical clinical questions rather than serve as large, definitive efficacy trials.

What kinds of interventions are eligible?

A wide range of investigational modalities are included, such as drugs and biologics, as well as surgical therapies and devices.

What are examples of the "early clinical questions" these trials should address?

Supported studies are intended to explore questions like feasibility in patients, whether early signals of safety or biological activity can be observed, and what parameters or outcomes should be used to design later clinical studies.

Is this funding meant for large, definitive clinical trials?

Based on the provided summary, the focus is on exploratory clinical trials and generating early human data to inform subsequent larger and more definitive clinical studies.

How does this opportunity help with later-stage development?

The intent is to generate credible early clinical evidence that supports next-step decisions, such as planning larger trials, shaping regulatory strategy, and making the case for further investment.

Which NIH institute is most relevant for alignment and priorities?

The opportunity emphasizes alignment with the National Institute of Neurological Disorders and Stroke (NINDS) strategic plan and its clinical research priorities.

Do projects need to align with NINDS priorities?

Yes. A key requirement is that the disease areas and proposed studies should align with the NINDS strategic plan and clinical research priorities, as reflected in NINDS programmatic interests.

Where can applicants check NINDS funding areas and clinical research topics?

The summary points to the NINDS website listing funding areas and topics at: http://www.ninds.nih.gov/funding/areas/index.htm

Who is eligible to apply?

Eligibility is restricted to small businesses, consistent with the small business innovation focus of the mechanism.

Are foreign organizations eligible to apply?

No. Foreign organizations are not eligible to apply.

Are non-U.S. components of U.S. organizations eligible?

No. Non-U.S. components of U.S. organizations are also not eligible to apply.

Can a U.S.-based applicant include any foreign work at all?

Possibly. The summary indicates that foreign components (as defined under the NIH Grants Policy Statement) may be allowed when they are well-justified, allowable under NIH policy, and appropriately described in the application.

What does "foreign component" mean here?

The summary references the NIH Grants Policy Statement definition. In general terms, it suggests a U.S.-based applicant may propose discrete elements of the project that take place outside the U.S. if allowed by NIH policy and justified in the application.

What is the funding category and activity area?

The opportunity is categorized as discretionary funding and falls under the health funding activity area.

What is the CFDA number listed for this opportunity?

The CFDA number provided in the summary is 93.853.

Which agency is sponsoring this announcement?

The sponsoring agency is the National Institutes of Health (NIH).

When was this announcement created?

The announcement was created on 2024-11-12.

What is the closing date for this opportunity?

The listed original closing date is 2027-09-05. The summary suggests a multi-year window during which applications may be accepted according to the program schedule and any stated receipt dates in the full announcement.

Does this mean applications can be submitted at any time until 2027-09-05?

Not necessarily. The summary notes a multi-year window, but also indicates that applications may be accepted according to the program schedule and any stated receipt dates in the full announcement. Applicants should check the full funding announcement for the actual receipt cycles and deadlines.

Is the award ceiling provided?

No. The provided summary does not specify an award ceiling.

Is the expected number of awards provided?

No. The provided summary does not specify the expected number of awards.

Where should applicants look for budget limits and project period expectations?

The summary indicates that applicants would need to consult the full funding announcement for details such as budget limits, project period expectations, and receipt cycles.

What stage of clinical development is this opportunity designed to support?

Based on the description, it is designed to support an early stage where a company needs credible human clinical evidence to inform larger trial planning, investment decisions, and regulatory strategy.

What neurological conditions are in scope?

The summary describes neurological conditions broadly and emphasizes that the specific disease area and research question should align with NINDS strategic priorities and programmatic interests.